NCT03403348View on ClinicalTrials.gov

A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

November 24, 2019

Study Completion Date

November 24, 2019

Conditions

Healthy

Interventions

DRUG

JNJ-64417184

Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

DRUG

Placebo

Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.

Trial Locations (2)

E1 2AX

hVIVO Services Limited, London

NW10 7EW

Hammersmith Medicines Research Ltd, London

All Listed Sponsors

lead

Janssen BioPharma, Inc.

INDUSTRY

NCT03403348 - A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants | Biotech Hunter | Biotech Hunter